Drug intelligence / Profile preview

OCN-300

Development stage: Preclinical
Lead developer: Onconic Therapeutics

Overview

OCN-300 is an early-stage oncology drug candidate being developed by Onconic Therapeutics, a subsidiary of Jeil Pharmaceutical. Currently in the discovery to preclinical phase, the compound is intended for the treatment of solid tumors. As of early 2024, specific details regarding its molecular target, mechanism of action, and modality have not been publicly disclosed by the company. It represents part of Onconic's expanding oncology pipeline, which also includes more advanced candidates like the dual PARP/tankyrase inhibitor OCN-201 (JPI-547).

Beyond the preview

Go deeper on OCN-300.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OCN-300.

Explore the full profile